SCHEMBL7189472

SCHEMBL7189472

CCC(C)(C)c1cc(-c2cc(C(C)(C)CC)cc(C(C)(C)CC)c2O)c(O)c(C(C)(C)CC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.40
MAPK1 P28482 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
CASP3 P42574 1/20 0.40
ATM Q13315 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HSP90AA1 P07900 1/20 0.37
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
RXRA P19793 5/20 0.33
PPARG P37231 5/20 0.33
RARG P13631 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065431 0.90 HSP90AA1 (0.46) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL1160345 0.90 SMN1; SMN2 (0.41) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL28069366 0.85 MAPK1 (0.43) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL11579489 0.84 ESR1 (0.50) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL8377448 0.84 SMN1; SMN2 (0.38) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL6111894 0.82 MAPK1 (0.35) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL10969248 0.82 CNR1 (0.40) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL22320301 0.81 MAPK1 (0.40) SMN1; SMN2MAPK1NPC1RAB9ALMNA
SCHEMBL8395315 0.81 CNR1 (0.38) HSP90AA1ESR1ESR2AR
SCHEMBL22320322 0.81 TSHR (0.48) SMN1; SMN2MAPK1NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797938-B1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2016-06-01 EP disclosed
EP-2797938-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2014-11-05 EP disclosed
US-8841474-B2 Process for preparing 6-chlorodibenzo[D,F][1,3,2]dioxaphosphepin BASF SE (DE) 2014-09-23 US disclosed
WO-2013098371-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 WO disclosed
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 US disclosed
US-6646148-B1 Rapid, selective, efficient, stable E. I. DU PONT DE NEMOURS AND COMPANY 2003-11-11 US disclosed
EP-0755302-B1 BIDENTATE PHOSPHITE AND NICKEL CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS DU PONT (US) 2000-10-04 EP disclosed
US-5910600-A Bisphosphite compound, process for its production and hydroformylation process employing the bisphosphite compound MITSUBISHI CHEMICAL CORPORATION (JP) 1999-06-08 US disclosed
EP-0861847-A2 Stabilizer composition and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-09-02 EP disclosed
EP-0755302-A1 BIDENTATE PHOSPHITE AND NICKEL CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-01-29 EP disclosed
WO-1995028228-A1 BIDENTATE PHOSPHITE AND NICKEL CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-10-26 WO disclosed
EP-0032681-B1 HINDERED BIS-PHENOL PHENYL PHOSPHITES AND SYNTHETIC RESIN COMPOSITIONS HAVING ENHANCED STABILITY TO HEAT AND LIGHT ADEKA ARGUS CHEMICAL CO., Ltd. (JP) 1987-07-22 EP disclosed
US-4362830-A Hindered bis-phenol phenyl phosphites and synthetic resin compositions having enhanced stability to heat and light ADEKA ARGUS CHEMICAL CO., LTD. (JP) 1982-12-07 US disclosed
EP-0032681-A2 Hindered bis-phenol phenyl phosphites and synthetic resin compositions having enhanced stability to heat and light ADEKA ARGUS CHEMICAL CO., Ltd. (JP) 1981-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN DCPS, PLCB3, DDT SMN1; SMN2 4810/4885MAPK1 1022/4885NPC1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.